MedTrace Logo

The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human

NCT05945394 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2023-09-13

No results posted yet for this study

Summary

To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human

Conditions

  • Coronary Heart Disease, Susceptibility to, 1

Interventions

OTHER

No intervention

This is an obvertional study, and there is no intervention.

Sponsors & Collaborators

  • Nanjing Medical University

    lead OTHER

Principal Investigators

  • Ma Shuren, MD · NJMU

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2023-10-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05945394 on ClinicalTrials.gov